These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 17706844

  • 1. Cost-utility analysis of vaccination against HPV in Israel.
    Ginsberg GM, Fisher M, Ben-Shahar I, Bornstein J.
    Vaccine; 2007 Sep 17; 25(37-38):6677-91. PubMed ID: 17706844
    [Abstract] [Full Text] [Related]

  • 2. Cost-utility analysis of interventions to reduce the burden of cervical cancer in Israel.
    Ginsberg GM.
    Vaccine; 2013 Nov 22; 31 Suppl 8():I46-52. PubMed ID: 24229719
    [Abstract] [Full Text] [Related]

  • 3. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
    Ginsberg GM, Edejer TT, Lauer JA, Sepulveda C.
    Vaccine; 2009 Oct 09; 27(43):6060-79. PubMed ID: 19647813
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM, van Ballegooijen M, Habbema JD.
    J Natl Cancer Inst; 2009 Aug 05; 101(15):1083-92. PubMed ID: 19571256
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
    Chen MK, Hung HF, Duffy S, Yen AM, Chen HH.
    J Eval Clin Pract; 2011 Dec 05; 17(6):1050-8. PubMed ID: 21679279
    [Abstract] [Full Text] [Related]

  • 6. Prevention strategies against the human papillomavirus: the effectiveness of vaccination.
    Stanley M.
    Gynecol Oncol; 2007 Nov 05; 107(2 Suppl 1):S19-23. PubMed ID: 17938013
    [Abstract] [Full Text] [Related]

  • 7. Mathematical models of cervical cancer prevention in the Asia Pacific region.
    Goldie SJ, Diaz M, Kim SY, Levin CE, Van Minh H, Kim JJ.
    Vaccine; 2008 Aug 19; 26 Suppl 12():M17-29. PubMed ID: 18945411
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of human papilloma virus vaccination in Iceland.
    Oddsson K, Johannsson J, Asgeirsdottir TL, Gudnason T.
    Acta Obstet Gynecol Scand; 2009 Aug 19; 88(12):1411-6. PubMed ID: 19900074
    [Abstract] [Full Text] [Related]

  • 9. Quadrivalent human papillomavirus vaccine.
    Barr E, Tamms G.
    Clin Infect Dis; 2007 Sep 01; 45(5):609-7. PubMed ID: 17682997
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.
    Vaccine; 2008 Jul 29; 26(32):4080-93. PubMed ID: 18550229
    [Abstract] [Full Text] [Related]

  • 12. Vaccination against HPV: indications for women and the impact on the cervical screening programme.
    Heideman DA, Snijders PJ, Berkhof J, Verheijen RH, Helmerhorst TJ, Meijer CJ.
    BJOG; 2008 Jul 29; 115(8):938-46. PubMed ID: 18651878
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of HPV 16, 18 vaccination in Brazil.
    Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, O'shea MK, Xavier Bosch F, de Sanjosé S, Franco EL.
    Vaccine; 2007 Aug 14; 25(33):6257-70. PubMed ID: 17606315
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The economic impact of HPV vaccines: not just cervical cancer.
    Myers ER.
    Am J Obstet Gynecol; 2008 May 14; 198(5):487-8. PubMed ID: 18455522
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy.
    Kim JJ, Kobus KE, Diaz M, O'Shea M, Van Minh H, Goldie SJ.
    Vaccine; 2008 Jul 29; 26(32):4015-24. PubMed ID: 18602731
    [Abstract] [Full Text] [Related]

  • 19. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
    Westra TA, Daemen T, Postma MJ, Wilschut JC.
    Ned Tijdschr Geneeskd; 2009 Jul 29; 153():A356. PubMed ID: 19930733
    [Abstract] [Full Text] [Related]

  • 20. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis.
    Yamamoto N, Mori R, Jacklin P, Osuga Y, Kawana K, Shibuya K, Taketani Y.
    BJOG; 2012 Jan 29; 119(2):177-86. PubMed ID: 21794070
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.